Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
Conditions: Schizophrenia; Treatment-resistant Schizophrenia; Side Effect; Lipid Metabolism Disorders; Diabetes; NAFLD; Psychosis Interventions: Drug: Aripiprazole; Drug: Paliperidone Sponsors: Consorcio Centro de Investigaci ón Biomédica en Red (CIBER); Instituto de Salud Carlos III Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration
ConclusionsThe declining use of LAI risperidone likely primarily reflects the substitution of a longer-acting LAI SGA, paliperidone, that came to market 2  yearsbefore the study publication, a substitution that may have been reinforced by null CSP#555 study results for LAI risperidone. (Source: Trials)
Source: Trials - February 6, 2023 Category: Research Source Type: clinical trials

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Condition:   Schizophrenia Interventions:   Drug: Risperidone 3 mg;   Drug: Paliperidone Palmitate 50 mg eq.;   Drug: Paliperidone Palmitate 75 mg eq.;   Drug: Paliperidone Palmitate 100 mg eq.;   Drug: Paliperidone Palmitate 150 mg eq.;   Drug: Paliperidone Palmitate 175 mg eq.;   Drug: Paliperidone Pa lmitate 263 mg eq.;   Drug: Paliperidone Palmitate 350 mg eq.;   Drug: Paliperidone Palmitate 525 mg eq. Sponsor:   Janssen-Cilag International NV Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 25, 2021 Category: Research Source Type: clinical trials